Evidence map›Paper›PMID 34845229›Full record

ArticleNature communications2021

The NUCKS1-SKP2-p21/p27 axis controls S phase entry.

Samuel Hume, Claudia P Grou, Pauline Lascaux, Vincenzo D'Angiolella, Arnaud J Legrand, Kristijan Ramadan, Grigory L Dianov

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Nutrients · 2026
    Article
  12. A pan-cancer analysis revealedPrecision clinical medicine · 2025
    Article
  13. Article
  14. Slice-PASEF: Maximising Ion Utilisation in LC-MS Proteomics.bioRxiv : the preprint server for biology · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Samuel HumeMedical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 7DQ, Oxford, UK.ORCID http://orcid.org/0000-0003-4417-0370
Claudia P GrouMedical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 7DQ, Oxford, UK.ORCID http://orcid.org/0000-0001-5197-2270
Pauline LascauxMedical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 7DQ, Oxford, UK.ORCID http://orcid.org/0000-0003-3935-6795
Vincenzo D'AngiolellaMedical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 7DQ, Oxford, UK.ORCID http://orcid.org/0000-0001-8365-9094
Arnaud J LegrandMedical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 7DQ, Oxford, UK. Arnaud.legrand@icr.ac.uk.ORCID http://orcid.org/0000-0002-9429-813X
Kristijan RamadanMedical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 7DQ, Oxford, UK. Kristijan.ramadan@oncology.ox.ac.uk.ORCID http://orcid.org/0000-0001-5522-021X
Grigory L DianovMedical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 7DQ, Oxford, UK. Grigory.dianov@oncology.ox.ac.uk.
University of Oxford · GBBreast Cancer Now · GBNovosibirsk State University · RU

Funding

Cancer Research UK C5255/A15935Medical Research Council H3RWGJ00.H302.1Medical Research Council MC_PC-12001/1Medical Research Council MC_PC_12001/1Medical Research Council MC_UU-00001/1Medical Research Council MC_UU_00001/1Medical Research Council MC_UU_00001/3Medical Research Council MC_UU_00001/7
6 · The paper itself

Abstract

Efficient entry into S phase of the cell cycle is necessary for embryonic development and tissue homoeostasis. However, unscheduled S phase entry triggers DNA damage and promotes oncogenesis, underlining the requirement for strict control. Here, we identify the NUCKS1-SKP2-p21/p27 axis as a checkpoint pathway for the G1/S transition. In response to mitogenic stimulation, NUCKS1, a transcription factor, is recruited to chromatin to activate expression of SKP2, the F-box component of the SCF

Indexed as

A549 CellsAnimalsBaculoviridaeCell Line, TumorCell ProliferationCell Transformation, NeoplasticCyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent Kinase Inhibitor p27DNA DamageGene Expression Regulation, NeoplasticHCT116 CellsHT29 CellsHumansNuclear ProteinsOsteoblastsPhosphoproteinsCyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent Kinase Inhibitor p27NUCKS1 protein, humanNuclear ProteinsPhosphoproteinsRecombinant ProteinsRNA, Small InterferingSKP2 protein, humanS-Phase Kinase-Associated ProteinsTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID34845229
PMCPMC8630071
OpenAlexW3215402579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.